Retatrutide
It is intended for the following purposes:
✔ As a complement to diet and physical activity to enhance glycemic control in adults with type 2 diabetes mellitus.
✔ To lower the risk of major cardiovascular events in patients with type 2 diabetes and diagnosed cardiovascular disease.
✔ To reduce liver fat infiltration and decrease inflammation markers associated with fatty liver.
✔ To promote weight loss and reduce body fat, which not only improves health outcomes but also serves as a measure of treatment efficacy for type 2 diabetes management.
Retatrutide
Сontains Retatrutide, a multi-functional peptide with triple receptor agonist activity targeting GIP (glucose-dependent insulinotropic polypeptide), GLP-1, and glucagon receptors.
Mechanism of Action
Retatrutide is a 39-amino acid peptide that simultaneously activates the glucagon receptor (GCGR), GIP receptor (GIPR), and GLP-1 receptor (GLP-1R). It features a C20 fatty diacid group that enhances its half-life and metabolic stability.
The structure of Retatrutide includes several modifications that resist degradation by dipeptidyl peptidase-4 (DPP4), enhancing its bioactivity. By acting on multiple receptors, Retatrutide improves insulin secretion, regulates glucagon production, and helps maintain stable blood sugar levels while promoting weight loss through reduced food intake and improved metabolic efficiency.
Pharmacodynamics
•Insulin Secretion & Sensitivity: The drug boosts both first- and second-phase insulin release while increasing insulin sensitivity, thus improving glucose metabolism.
•Glucagon Modulation: Retatrutide competes with the natural ligand at glucagon receptors, reducing glucagon secretion by approximately 70%, aiding in better blood sugar regulation.
•Gastric Emptying: By delaying gastric emptying, Retatrutide slows glucose absorption after meals, leading to more gradual blood sugar increases and reduced appetite.
•Liver Fat and Inflammation Reduction: Clinical studies have demonstrated that Retatrutide decreases hepatic fat content within 24 weeks, with further improvements by week 48, including reduced markers of insulin resistance and liver inflammation.
Clinical Research Results
The TRIUMPH clinical trial (Phases 1 and 2) assessed the efficacy of Retatrutide in managing chronic weight issues, sleep apnea, and osteoarthritis in obese and overweight individuals.
•At 24 weeks, weight loss averaged up to 17.5% (41.2 lbs or 18.7 kg).
•By 48 weeks, the weight reduction reached 24.2% (57.8 lbs or 26.2 kg) in participants receiving 12 mg weekly.Participants were stratified by BMI and sex and randomly assigned to receive varying doses of Retatrutide (1 mg, 4 mg, 8 mg, or 12 mg) or placebo. All participants received structured lifestyle counseling in line with U.S. dietary and physical activity guidelines.
Key Outcomes:
•7.2% for the 1 mg group
•13.9% for the 4 mg group with a starting dose of 4 mg
•17.9% for the 8 mg group with a starting dose of 4 mg
•17.5% for the 12 mg group
•1.6% for the placebo group
•Weight reduction at 48 weeks:
•8.7% for the 1 mg group
•17.8% for the 4 mg group with a starting dose of 4 mg
•23.9% for the 8 mg group with a starting dose of 4 mg
•24.2% for the 12 mg group
•2.1% for the placebo group
Additional Observations:
•Participants experienced significant improvements in cardiometabolic markers, including reductions in waist circumference, blood pressure, and LDL cholesterol.
•72% of those with prediabetes reverted to normoglycemia by the end of the trial.
These findings highlight Retatrutide’s efficacy in surpassing typical weight-loss targets set by other anti-obesity treatments, prompting potential re-evaluation of weight-loss goals in clinical guidelines.
Dosage and Administration
•2 mg subcutaneously once weekly to reduce gastrointestinal side effects and assess individual tolerance.
Titration:
•Increase to 4 mg weekly after 2 weeks.
•Further dosage adjustments may be made in 1 mg increments every 2 weeks based on patient needs, up to a maximum dose of 8 mg per week.
Missed Dose Instructions:
•Administer the missed dose within 96 hours. If more than 4 days have passed, skip the dose and resume the regular schedule.
Injection Guidelines:
•Inject subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites to prevent irritation.
•When used alongside insulin, administer injections separately. Do not mix Retatrutide with insulin.
Contraindications and Side Effects
•A personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
•Known hypersensitivity to Retatrutide or its components.
Common Adverse Effects:
•Decreased appetite, nausea, constipation, and diarrhea.
•Transient gastrointestinal issues, which are dose-dependent and primarily occur during dose escalation.
•Mild increases in heart rate.
⚠ Warning!
This medication is not intended for patients with type 1 diabetes.
Sunsci.io
Tirzepatide is a modern drug for safe and effective body weight control, belonging to the class of incretin drugs.